Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC).
From Cell Signaling TechnologySep 20 2023Reviewed by Danielle Ellis, B.Sc. Leica is a global market leader in enabling the translation of pre-clinical research into CDx tests, helping pharma partners develop and commercialize cutting-edge diagnostic solutions to identify patients likely to benefit from emerging therapeutics.
Clinical trial recruitment and assessment of patient biomarker status are dependent on the use of effective and reliable CDx assays as a critical component of guiding treatment decisions for personalized medicine. Since 2020, this agreement has facilitated the use of trusted CST® antibodies to unique biomarkers by the Leica Biosystems CDx team to enable leading biotechnology and pharmaceutical companies to leverage these fit-for-purpose tools to support the drug development workflow.
Related Stories“Ensuring the availability of trusted, highly validated antibody products from initial discovery through translation and CDx development streamlines the pharmaceutical development process and de-risks product commercialization,” said Roberto Polakiewicz, Chief Scientific Officer at CST. “Strategic partnerships like this help drive precision medicine forward by enabling more rapid and efficient development of new therapies to devastating diseases.
Since the establishment of our Companion Diagnostics Team in 2012, our expertise in immunohistochemistry, in situ hybridization, and automation has enabled assay development for a diverse range of biomarker targets across a variety of cancer types for our Biopharma partners. We are excited to collaborate with CST to develop transformative companion diagnostics for the advancement of personalized medicine for cancer patients.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Cell Signaling Technology and Beyond Benign collaborate to advance green chemistry educationCell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership with global green chemistry education nonprofit Beyond Benign.
Weiterlesen »
Wireless molecular-electrical communications for tumor-cell-induced apoptosisResearchers utilize electricity generated by wireless-induced redox interactions at bio-nanoantennae to cause apoptosis in cancerous cells.
Weiterlesen »
Single-cell screening of cerebral organoids to identify developmental defects in autismResearchers develop CRISPR-human organoids-single-cell RNA sequencing system to identify developmental brain defects in autism.
Weiterlesen »
3D stress patterns in capillaries found to be caused by red blood cell squeezingNew and unique shear stress patterns can occur in angiogenic capillary (new blood vessel growth) networks, according to a new study titled 'Angiogenic microvascular wall shear stress patterns revealed through three-dimensional red blood cell resolved modeling' published in the journal Function. There was also enhancement of low shear stress regions by red blood cells. Shear stress is the frictional force of the blood on the vessel wall.
Weiterlesen »
Cell therapy can reduce risk of death from COVID-19 by 60%, study findsThe use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
Weiterlesen »
Uniink: A new 3D bioprinted cell therapy approach for Type 1 diabetesJavier Ramón Azcón, an ICREA research professor and the leader of the Biosensors for Bioengineering group at the Institute for Bioengineering of Catalonia (IBEC), has been granted an 'ERC Proof of Concept Grant.'
Weiterlesen »